Valneva (NASDAQ:VALN) Shares Gap Up to $8.04

Valneva SE (NASDAQ:VALN) gapped up before the market opened on Wednesday . The stock had previously closed at $8.04, but opened at $8.38. Valneva shares last traded at $8.46, with a volume of 1,293 shares changing hands.

Analyst Ratings Changes

VALN has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $26.00 price objective on shares of Valneva in a report on Thursday, March 21st. Guggenheim decreased their price objective on Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a report on Friday, March 22nd.

Valneva Stock Performance

The firm has a fifty day moving average price of $7.67 and a 200 day moving average price of $9.77. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.37 and a current ratio of 1.65. The stock has a market cap of $617.49 million, a PE ratio of -5.63 and a beta of 2.25.

Institutional Trading of Valneva

Several hedge funds and other institutional investors have recently made changes to their positions in VALN. UBS Group AG purchased a new stake in Valneva during the 2nd quarter valued at about $31,000. Bank of America Corp DE acquired a new stake in shares of Valneva during the first quarter worth about $858,000. Finally, Jane Street Group LLC boosted its position in Valneva by 85.9% in the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock valued at $569,000 after buying an additional 7,664 shares during the last quarter. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.